8-K: PepGen Faces FDA Hold on DM1 Trial, Reports 2025 Financials

PepGen Inc. announced a partial clinical hold on its FREEDOM2-DM1 Phase 2 trial by the U.S. FDA, alongside its year-end 2025 financial results and positive Phase 1 data.

Summary

• PepGen Inc. reported its financial results for the year ended December 31, 2025, and provided corporate and clinical updates.
• The U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1, citing questions related to previously submitted preclinical pharmacology and toxicology studies.
• The company expects to report results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026 and from the 10 mg/kg cohort in 2H 2026.
• Positive unblinded final results from the Phase 1 FREEDOM-DM1 study showed dose-proportional increases in muscle tissue concentration and splicing correction, reaching 53.7% at 15 mg/kg.
• PepGen ended 2025 with $148.5 million in cash, cash equivalents, and marketable securities, projected to fund operations into the second half of 2027.
• Joseph Vittiglio, Esq., was appointed Chief Business and Legal Officer in December 2025.
• A new composition of matter patent for PGN-EDODM1 was issued in November 2025, providing U.S. exclusivity into 2H 2042.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative update. While strong Phase 1 data and a solid cash position are positives, the FDA partial clinical hold on a key Phase 2 trial introduces significant uncertainty and potential delays, outweighing the positive financial and patent news.

Positives

• Ended 2025 with a strong cash position of $148.5 million, sufficient to fund operations into the second half of 2027.
• Phase 1 FREEDOM trial delivered compelling data, showing robust target engagement and unprecedented mean splicing correction levels (12.3% at 5 mg/kg, 29.1% at 10 mg/kg, and 53.7% at 15 mg/kg) after a single dose.
• PGN-EDODM1 was generally well-tolerated across all doses in the Phase 1 trial, with mild to moderate, transient adverse events.
• The Data Safety Monitoring Board (DSMB) recommended dose escalation to 10 mg/kg in the FREEDOM2 trial, and 50% of patients (4/8) in this cohort have already been dosed.
• Received regulatory clearance to initiate the FREEDOM2 trial in South Korea, Australia, and New Zealand, expanding global reach.
• A new composition of matter patent for PGN-EDODM1 was issued by the USPTO, providing exclusivity in the U.S. into the second half of 2042, with potential for extension.
• PGN-EDODM1 has received Orphan Drug and Fast Track Designations from the U.S. FDA and Orphan Designation from the European Medicines Agency (EMA).
• Net loss for the year ended December 31, 2025, decreased slightly to $89.7 million from $90.0 million in 2024.
• Research and Development Expenses decreased to $71.0 million for the year ended December 31, 2025, from $76.5 million in 2024.

Negatives

• The U.S. FDA placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 trial, which could delay development and approval in the U.S.
• The partial clinical hold relates to previously submitted preclinical pharmacology and toxicology studies, indicating potential concerns with the foundational data.
• General and Administrative Expenses increased to $22.6 million for the year ended December 31, 2025, from $21.3 million in 2024.
• Interest income decreased to $4.017 million for the year ended December 31, 2025, from $7.142 million in 2024.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates, including PGN-EDODM1.
• Inability to enroll patients in clinical trials, including FREEDOM2.
• Interpretation of clinical and preclinical study results may be incorrect, or anticipated levels of therapeutic activity may not be observed in clinical testing.
• Product candidates, including PGN-EDODM1, may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review, clearance to proceed with planned clinical studies, or approval by regulatory authorities.
• The partial clinical hold placed by the FDA on the FREEDOM2 study may not be released, or other regulatory feedback may require modifications to development programs.
• Changes in the regulatory framework that are outside of the company's control.
• Unexpected increases in expenses associated with development activities or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for some or all aspects of product manufacturing, research, and preclinical and clinical testing.

Future Outlook

The company anticipates reporting results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026 and from the 10 mg/kg cohort in 2H 2026. It also expects its current cash reserves of $148.5 million to fund operations into the second half of 2027. PepGen aims to address the FDA's questions regarding the partial clinical hold as quickly as possible and believes PGN-EDODM1 has the potential to be a best-in-class treatment for DM1.

Management Comments

• "2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing correction in DM1, reinforced our conviction in PGN-EDODM1 as a potential best-in-class treatment, and further demonstrated the differentiated potential of our EDO platform." James McArthur, PhD, President and CEO.
• "After a single dose, we observed robust target engagement beginning at the lowest dose of 5 mg/kg — a finding that exceeded our expectations and underscored the potency of our drug candidate." James McArthur, PhD, President and CEO.
• "Based on the totality of FREEDOM data, we believe that doses of 10 mg/kg could potentially offer a best-in-class treatment option for people living with this serious disease." James McArthur, PhD, President and CEO.
• "As we prepare for the 5 mg/kg dose cohort readout from our ongoing randomized, placebo-controlled multiple ascending dose Phase 2 FREEDOM2 study later this quarter, we are focused on building upon the robust muscle oligonucleotide levels and splicing correction observed in FREEDOM, with the goal of translating sustained exposure into meaningful functional benefit." James McArthur, PhD, President and CEO.
• "PepGen is entering this new year with strong momentum and a clear path toward potentially delivering a meaningful new treatment for the DM1 community." James McArthur, PhD, President and CEO.
• "The Company is committed to working with the FDA to address the Agency’s questions as quickly as possible."

Industry Context

StockSavvy.ai notes that the partial clinical hold by the FDA is a significant setback for PepGen, a clinical-stage biotechnology company operating in the competitive neuromuscular and neurological disease space. While the company has demonstrated promising Phase 1 data for PGN-EDODM1 in Myotonic Dystrophy Type 1 (DM1) and secured a key patent, regulatory hurdles are common in drug development and can severely impact timelines and investor confidence. The expansion of the FREEDOM2 trial into South Korea, Australia, and New Zealand, along with continued dosing in Canada and the UK, indicates a strategy to mitigate U.S. regulatory delays by advancing the program internationally. The DM1 therapeutic landscape is evolving, with several companies pursuing oligonucleotide-based therapies, making rapid and clear clinical progress crucial for market positioning.

Comparison to Industry Standards

• PGN-EDODM1's Phase 1 data, demonstrating mean splicing correction of 53.7% at 15 mg/kg, is stated to have "set a new benchmark for splicing correction in DM1," suggesting a potentially superior efficacy profile compared to existing or other investigational therapies in this specific metric.
• The receipt of Orphan Drug and Fast Track Designations from the U.S. FDA and Orphan Designation from the European Medicines Agency (EMA) indicates that PGN-EDODM1 meets recognized industry criteria for addressing rare diseases with significant unmet medical needs.
• The partial clinical hold by the FDA, while a setback, is a common occurrence in the highly regulated biotechnology industry, reflecting the rigorous scrutiny applied to novel drug candidates, particularly concerning preclinical safety and toxicology data.

Management Changes

Stakeholder Impact

• Shareholders: Potential negative impact due to increased regulatory risk and uncertainty surrounding the FREEDOM2 trial, which could affect stock price.
• Patients (DM1): Potential delay in access to a promising investigational therapy in the U.S., though international trials continue.
• Employees: Continued focus on addressing regulatory concerns and advancing clinical programs.
• Regulatory Authorities (FDA): Engaged in dialogue with the company to ensure safety and efficacy standards are met.

Next Steps

• Report results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026.
• Continue dosing patients in the 10 mg/kg cohort of the FREEDOM2 trial in Canada and the UK.
• Report results from the 10 mg/kg cohort of the FREEDOM2 trial in 2H 2026.
• Work with the FDA to address questions related to the partial clinical hold on the FREEDOM2 study.
• Present unblinded final results from the FREEDOM-DM1 Phase 1 study at the 2026 MDA Clinical & Scientific Conference (March 8-11, 2026).
• Open the Open Label Extension (OLE) study in all geographies where FREEDOM2 is open.
• Open sites for the FREEDOM2 trial in New Zealand and Australia.

Key Dates

Recommendation

While PepGen's Phase 1 data for PGN-EDODM1 is highly promising and the company maintains a strong cash position, the partial clinical hold by the FDA introduces significant uncertainty and potential delays for its pivotal Phase 2 trial in the crucial U.S. market. This regulatory setback creates a period of elevated risk. Investors should hold to monitor the resolution of the FDA hold and further clinical data, as the long-term potential remains if these issues are successfully addressed, but immediate upside is constrained by regulatory headwinds.

Keywords

Myotonic Dystrophy Type 1, DM1, PGN-EDODM1, FREEDOM2, Clinical Hold, FDA, Biotechnology, Oligonucleotide Therapy, Neuromuscular Disease, SEC Filing, Financial Results, Drug Development, Clinical Trial, Orphan Drug, Fast Track Designation, Patent